Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hana Biosciences has reported that it will halt the development of the original formulation of Zensana its drug for the prevention of nausea and vomiting as a result of chemotherapy, radiation, and surgery.
Subscribe to our email newsletter
The decision came after the company’s investigation of a previously reported precipitation issue. As a result, Hana has chosen to withdraw a new drug application previously submitted to the FDA, without prejudice.
In June 2006, Hana submitted a new drug application for Zensana with the FDA to seek approval for the prevention of nausea and vomiting as a result of chemotherapy, radiation, and surgery.
Hana’s partner and licensor, NovaDel Pharma, has developed an alternate formulation of the product. This new formulation is currently under active investigation and scale-up, and Hana plans to work with NovaDel to evaluate the new formulation.